Mitomycin-C induced hemolytic uremic syndrome: a case report.
Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome. We report a patient with a colonic adenocarcinoma who developed hemolytic uremic syndrome after receiving 85 mg/m2 of the drug. The patient was left untreated and died 5 months after this diagnosis was made, of a second malignancy. Differential diagnosis and treatment of this condition are discussed.
Gundappa
Rajaram K
RK
Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Sud
Kamal
K
Kohli
Harbir S
HS
Gupta
Krishan L
KL
Joshi
Kusum
K
Sakhuja
Vinay
V
D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy; D000477:Alkylating Agents / Q000009:adverse effects*; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D003110:Colonic Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D003937:Diagnosis, Differential; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin / Q000009:adverse effects*; D051437:Renal Insufficiency / Q000139:chemically induced / Q000175:diagnosis
D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D016685:Mitomycin